SEI Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

SEI Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Sell	145,683 -4,581	-3%	-$41.4K	﹤0.01%	2113
2026 Q1	$1.43M	Buy	150,264 +47,107	+46%	+$366K	﹤0.01%	2175
2025 Q4	$805K	Sell	103,157 -259,059	-72%	-$1.87M	﹤0.01%	2277
2025 Q3	$2.75M	Buy	362,216 +138,973	+62%	+$1.16M	﹤0.01%	1568
2025 Q2	$2M	Buy	223,243 +113,776	+104%	+$1.06M	﹤0.01%	1651
2025 Q1	$821K	Buy	109,467 +52,277	+91%	+$422K	﹤0.01%	1983
2024 Q4	$430K	Buy	57,190 +1,537	+3%	+$11.7K	﹤0.01%	2235
2024 Q3	$423K	Buy	55,653 +13,806	+33%	+$105K	﹤0.01%	2238
2024 Q2	$259K	Sell	41,847 -385	-0.9%	-$2.13K	﹤0.01%	2391
2024 Q1	$215K	Buy	42,232 +3,070	+8%	+$17.3K	﹤0.01%	2408
2023 Q4	$235K	Buy	39,162 +1,156	+3%	+$6.7K	﹤0.01%	2399
2023 Q3	$269K	Buy	38,006 +11,011	+41%	+$79.1K	﹤0.01%	2340
2023 Q2	$190K	Sell	26,995 -16,509	-38%	-$132K	﹤0.01%	2486
2023 Q1	$363K	Sell	43,504 -28,906	-40%	-$278K	﹤0.01%	2260
2022 Q4	$831K	Buy	72,410 +46,227	+177%	+$576K	﹤0.01%	1830
2022 Q3	$330K	Sell	26,183 -3,233	-11%	-$41.6K	﹤0.01%	2267
2022 Q2	$311K	Sell	29,416 -49,237	-63%	-$508K	﹤0.01%	2305
2022 Q1	$1.28M	Buy	78,653 +42,925	+120%	+$689K	﹤0.01%	1725
2021 Q4	$495K	Sell	35,728 -44,405	-55%	-$588K	﹤0.01%	2108
2021 Q3	$1.15M	Sell	80,133 -38,604	-33%	-$609K	﹤0.01%	1733
2021 Q2	$1.88M	Buy	+118,737	New	+$1.61M	﹤0.01%	1541
2020 Q3	–	Sell	-94,898	Closed	-$452K	–	2409
2020 Q2	$452K	Buy	+94,898	New	+$379K	﹤0.01%	1900
2019 Q2	–	Sell	-59,358	Closed	-$483K	–	2416
2019 Q1	$483K	Sell	59,358 -16,472	-22%	-$141K	﹤0.01%	1907
2018 Q4	$612K	Buy	+75,830	New	+$590K	﹤0.01%	1697
2018 Q3	–	Sell	-588	Closed	-$4K	–	2562
2018 Q2	$4K	Hold	588	–	–	﹤0.01%	3188
2018 Q1	$3K	Hold	588	–	–	﹤0.01%	3146
2017 Q4	$3K	Hold	588	–	–	﹤0.01%	3022
2017 Q3	$3K	Buy	588 +146	+33%	+$748	﹤0.01%	2909
2017 Q2	$2K	Hold	442	–	–	﹤0.01%	2854
2017 Q1	$4K	Hold	442	–	–	﹤0.01%	2605
2016 Q4	$3K	Hold	442	–	–	﹤0.01%	2652
2016 Q3	$2K	Hold	442	–	–	﹤0.01%	2633
2016 Q2	$1K	Buy	+442	New	+$1.37K	﹤0.01%	2526
2015 Q4	–	Sell	-27,734	Closed	-$316K	–	2528
2015 Q3	$316K	Buy	+27,734	New	+$370K	﹤0.01%	1459

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SEI Investments's BCRX Position: Q2 2026 in Review

SEI Investments reduced its BioCryst Pharmaceuticals (BCRX) stake by 3% in Q2 2026, selling an estimated $41.4K and leaving 145,683 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2113.

SEI Investments first reported a position in BCRX in Q3 2015 and has held it in 34 quarters since. The position peaked at $2.75M in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

SEI Investments held 145,683 shares of BioCryst Pharmaceuticals worth $1.46M as of Q2 2026.
SEI Investments sold 4,581 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $41.4K.
BioCryst Pharmaceuticals made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2113 holding.
SEI Investments first reported a position in BioCryst Pharmaceuticals in Q3 2015 and has held it in 34 quarters since.
SEI Investments's BioCryst Pharmaceuticals position peaked at $2.75M in Q3 2025.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.